RLYB

Rallybio Corporation

1.83 USD
+0.03 (+1.67%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Rallybio Corporation stock is up 31.65% since 30 days ago. The next earnings date is Mar 4, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 66.67% of the previous 2 February’s closed higher than January. 75% of analysts rate it a buy.

About Rallybio Corporation

Rallybio Corporation engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that is in Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT)

  • JP Morgan
    Wed Feb 7, 11:19
    buy
    confirm
  • Wedbush
    Wed Feb 7, 08:22
    buy
    confirm
  • Jefferies
    Wed Feb 7, 07:00
    hold
    downgrade
  • HC Wainwright & Co.
    Wed Feb 7, 06:25
    buy
    confirm